Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnovivaINVA -2.30%88 FCF Yield % is 11.43 as of Jul. 18, 2026, which is 10% below its 10-year median of 12.77. GuruFocus rates INVA with a GF Score™ of 88/100 and a GF Value™ of $20.45 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,409 Biotechnology companies, Innoviva ranks better than 97.59% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Innoviva FCF Yield % Related Terms
Innoviva FCF Yield % Historical Data
* Premium members only.
The historical data trend for Innoviva's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innoviva's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innoviva FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innoviva's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Innoviva's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innoviva (INVA) has a FCF Yield % of 11.43 as of Jul. 18, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Innoviva and its competitors. This is 10% below median its historical median of 12.77. Over the past decade, Innoviva's FCF Yield % has ranged from 1.83 to 32.98. According to the industry distribution chart, Innoviva ranks #34 out of 1409 companies in the Biotechnology industry, placing it in the top 2.4%.
Is Innoviva's FCF Yield % too high?
Innoviva's current FCF Yield % of 11.43 is 10% below median its 10-year median of 12.77. Over the past 10 years, this metric has ranged from a low of 1.83 to a high of 32.98. Based on the distribution chart, Innoviva ranks #34 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Innoviva has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innoviva's FCF Yield % compare to BCAX and ZYME?
According to the Biotechnology industry distribution chart, Innoviva ranks #34 out of 1409 companies for FCF Yield %. This places Innoviva in the top 2% of its industry — outperforming the majority of peers. Historically, Innoviva's own FCF Yield % has ranged from 1.83 to 32.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Innoviva and its competitors. Innoviva's current FCF Yield % is 11.43, which is 10% below median its own 10-year median of 12.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innoviva stock overvalued right now?
Based on GuruFocus' analysis, Innoviva (INVA) is currently considered Fairly Valued. The stock's GF Value™ is $20.45, compared to a current price of $21.71 — trading 6.2% above its estimated fair value. The current FCF Yield % is 11.43, which is 10% below median its 10-year median of 12.77. Innoviva's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Innoviva (INVA), the current FCF Yield % is 11.43 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innoviva (INVA) Overvalued in 2026?
Based on GuruFocus' analysis, Innoviva stock appears to be overvalued.
The current stock price of $21.71 is trading 6.2% above its estimated GF Value™ of $20.45.
GuruFocus considers Innoviva to be Fairly Valued.
Key valuation signals for INVA:
FCF Yield %: 11.43 (10% below median its 10-year median of 12.77)
GF Value™: $20.45 vs. price of $21.71 (6.2% above fair value)
No single metric tells the full story. See the INVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
88GF Score
Get the complete analysis for INVA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INVA has been successfully added to your 
